aTyr Pharma (LIFE) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

LIFE Stock Forecast

aTyr Pharma stock forecast is as follows: an average price target of $11.00 (represents a 623.68% upside from LIFE’s last price of $1.52) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

LIFE Price Target

The average price target for aTyr Pharma (LIFE) is $11.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 623.68% upside from LIFE's last price of $1.52.

LIFE Analyst Ratings

Buy

According to 1 Wall Street analysts, aTyr Pharma's rating consensus is 'Buy'. The analyst rating breakdown for LIFE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

aTyr Pharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 18, 2022		Piper Sandler	$11.00	$3.20	243.75%	623.68%

The latest aTyr Pharma stock forecast, released on May 18, 2022 by Piper Sandler company, set a price target of $11.00, which represents a 243.75% increase from the stock price at the time of the forecast ($3.20), and a 623.68% increase from LIFE last price ($1.52).

aTyr Pharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$1.52	$1.52	$1.52
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of aTyr Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to aTyr Pharma's last price of $1.52. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Aug 14, 2024	Piper Sandler	Overweight	Overweight	Hold
Jul 05, 2023	Oppenheimer		Perform	Downgrade
Aug 15, 2022	Piper Sandler	Overweight	Overweight	Hold
May 18, 2022	Piper Sandler	Overweight	Overweight	Hold

aTyr Pharma's last stock rating was published by Piper Sandler on Aug 14, 2024. The company gave LIFE a "Overweight" rating, the same as its previous rate.

aTyr Pharma Financial Forecast

aTyr Pharma Revenue Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$10.39M	-	-	-	-	-	-	-	$2.05M	-	-	$8.06M	$144.00K	-
Avg Forecast	$144.87K	$155.24K	$166.34K	$178.25K	$5.00K	$32.50K	$30.00K	$36.67K	$3.42M	$1.50M	$611.67K	$2.36M	$357.14K	$400.00K	$2.50M	$200.00K	$2.52M	$266.67K	$621.80K	$3.98M	$126.00K	$103.33K	$399.10K	$4.40M	$155.77K	$60.00K
High Forecast	$144.87K	$155.24K	$166.34K	$178.25K	$5.00K	$32.50K	$30.00K	$36.83K	$3.42M	$1.50M	$611.67K	$2.36M	$357.14K	$400.00K	$2.50M	$200.00K	$2.52M	$266.67K	$621.80K	$3.98M	$126.00K	$103.33K	$399.10K	$4.40M	$155.77K	$60.00K
Low Forecast	$144.87K	$155.24K	$166.34K	$178.25K	$5.00K	$32.50K	$30.00K	$36.50K	$3.42M	$1.50M	$611.67K	$2.36M	$357.14K	$400.00K	$2.50M	$200.00K	$2.52M	$266.67K	$621.80K	$3.98M	$126.00K	$103.33K	$399.10K	$4.40M	$155.77K	$60.00K
# Analysts	1	1	1	1	2	2	3	2	3	1	1	1	1	1	1	1	2	2	2	2	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	29.08%	-	-	-	-	-	-	-	16.29%	-	-	1.83%	0.92%	-

aTyr Pharma's average Quarter revenue forecast for Mar 23 based on 1 analysts is $2.36M, with a low forecast of $2.36M, and a high forecast of $2.36M. LIFE's average Quarter revenue forecast represents a -77.24% decrease compared to the company's last Quarter revenue of $10.39M (Dec 22).

aTyr Pharma EBITDA Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
# Analysts	1	1	1	1	2	2	3	2	3	1	1	1	1	1	1	1	2	2	2	2	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-12.03M	$-7.95M	-	-	$-12.08M	$-8.24M	-	-	$-6.85M	$-4.69M	-	-	$2.11M	$-5.62M	-
Avg Forecast	$-86.92K	$-93.14K	$-99.81K	$-106.95K	$-3.00K	$-19.50K	$-18.00K	$-22.00K	$-2.05M	$-900.00K	$-367.00K	$-1.42M	$-214.28K	$-240.00K	$-1.50M	$-8.05M	$-1.51M	$-160.00K	$-373.08K	$-3.09M	$-75.60K	$-62.00K	$-239.46K	$-2.64M	$-93.46K	$-36.00K
High Forecast	$-86.92K	$-93.14K	$-99.81K	$-106.95K	$-3.00K	$-19.50K	$-18.00K	$-21.90K	$-2.05M	$-900.00K	$-367.00K	$-1.42M	$-214.28K	$-240.00K	$-1.50M	$-6.44M	$-1.51M	$-160.00K	$-373.08K	$-2.47M	$-75.60K	$-62.00K	$-239.46K	$-2.64M	$-93.46K	$-36.00K
Low Forecast	$-86.92K	$-93.14K	$-99.81K	$-106.95K	$-3.00K	$-19.50K	$-18.00K	$-22.10K	$-2.05M	$-900.00K	$-367.00K	$-1.42M	$-214.28K	$-240.00K	$-1.50M	$-9.66M	$-1.51M	$-160.00K	$-373.08K	$-3.70M	$-75.60K	$-62.00K	$-239.46K	$-2.64M	$-93.46K	$-36.00K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	8.48%	37.10%	-	-	1.50%	5.46%	-	-	2.22%	61.98%	-	-	-0.80%	60.14%	-

1 analysts predict LIFE's average Quarter EBITDA for Jul 20 to be $-239.46K, with a high of $-239.46K and a low of $-239.46K. This is -111.34% lower than aTyr Pharma's previous annual EBITDA (Mar 20) of $2.11M.

aTyr Pharma Net Income Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
# Analysts	1	1	1	1	2	2	3	2	3	1	1	1	1	1	1	1	2	2	2	2	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-11.12M	$-7.09M	-	-	$-11.93M	$-8.56M	-	-	$-7.15M	$-4.93M	-	-	$1.75M	$-5.97M	-
Avg Forecast	$-5.29M	$-6.61M	$-10.57M	$-10.57M	$-14.93M	$-15.73M	$-15.73M	$-16.52M	$-15.73M	$-14.93M	$-18.41M	$-23.13M	$-31.72M	$-30.62M	$-25.24M	$-8.10M	$-18.72M	$-39.18M	$-33.57M	$-3.20M	$-54.41M	$-49.12M	$-48.24M	$5.35M	$-105.07M	$-114.10M
High Forecast	$-5.29M	$-6.61M	$-10.57M	$-10.57M	$-14.93M	$-15.73M	$-13.58M	$-16.52M	$-13.91M	$-14.93M	$-18.41M	$-23.13M	$-31.72M	$-30.62M	$-25.24M	$-6.48M	$-18.72M	$-39.18M	$-33.57M	$-2.56M	$-54.41M	$-49.12M	$-48.24M	$6.42M	$-105.07M	$-114.10M
Low Forecast	$-5.29M	$-6.61M	$-10.57M	$-10.57M	$-14.93M	$-15.73M	$-17.87M	$-16.52M	$-16.94M	$-14.93M	$-18.41M	$-23.13M	$-31.72M	$-30.62M	$-25.24M	$-9.72M	$-18.72M	$-39.18M	$-33.57M	$-3.83M	$-54.41M	$-49.12M	$-48.24M	$4.28M	$-105.07M	$-114.10M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.48%	0.22%	-	-	1.47%	0.46%	-	-	2.24%	0.09%	-	-	0.33%	0.06%	-

aTyr Pharma's average Quarter net income forecast for Jul 20 is $-48.24M, with a range of $-48.24M to $-48.24M. LIFE's average Quarter net income forecast represents a -2851.79% decrease compared to the company's last Quarter net income of $1.75M (Mar 20).

aTyr Pharma SG&A Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
# Analysts	1	1	1	1	2	2	3	2	3	1	1	1	1	1	1	1	2	2	2	2	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	$3.41M	$3.43M	-	-	$3.48M	$2.69M	-	-	$2.69M	$2.29M	-	-	$2.59M	$2.52M	-
Avg Forecast	$1.58M	$1.69M	$1.81M	$1.94M	$54.38K	$353.46K	$326.27K	$398.78K	$37.19M	$16.31M	$6.65M	$25.71M	$3.88M	$4.35M	$27.19M	$2.18M	$27.37M	$2.90M	$6.76M	$1.20M	$1.37M	$1.12M	$4.34M	$47.84M	$1.69M	$652.54K
High Forecast	$1.58M	$1.69M	$1.81M	$1.94M	$54.38K	$353.46K	$326.27K	$400.58K	$37.19M	$16.31M	$6.65M	$25.71M	$3.88M	$4.35M	$27.19M	$2.18M	$27.37M	$2.90M	$6.76M	$1.44M	$1.37M	$1.12M	$4.34M	$47.84M	$1.69M	$652.54K
Low Forecast	$1.58M	$1.69M	$1.81M	$1.94M	$54.38K	$353.46K	$326.27K	$396.96K	$37.19M	$16.31M	$6.65M	$25.71M	$3.88M	$4.35M	$27.19M	$2.18M	$27.37M	$2.90M	$6.76M	$960.25K	$1.37M	$1.12M	$4.34M	$47.84M	$1.69M	$652.54K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.13%	0.88%	-	-	1.60%	0.10%	-	-	2.24%	1.67%	-	-	0.05%	1.49%	-

aTyr Pharma's average Quarter SG&A projection for Jul 23 is $6.65M, based on 1 Wall Street analysts, with a range of $6.65M to $6.65M. The forecast indicates a 95.20% rise compared to LIFE last annual SG&A of $3.41M (Mar 23).

aTyr Pharma EPS Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19
# Analysts	1	1	1	1	2	2	3	2	3	1	1	1	1	1	1	1	2	2	2	2	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.27	$-0.24	-	-	$-0.43	$-0.31	-	-	$-0.51	$-0.47	-	-	$0.25	$-1.54	-
Avg Forecast	$-0.08	$-0.10	$-0.16	$-0.16	$-0.23	$-0.24	$-0.24	$-0.25	$-0.24	$-0.23	$-0.28	$-0.35	$-0.48	$-0.46	$-0.38	$-0.32	$-0.28	$-0.59	$-0.51	$-0.32	$-0.82	$-0.74	$-0.73	$-0.18	$-1.59	$-1.73
High Forecast	$-0.08	$-0.10	$-0.16	$-0.16	$-0.23	$-0.24	$-0.21	$-0.25	$-0.21	$-0.23	$-0.28	$-0.35	$-0.48	$-0.46	$-0.38	$-0.32	$-0.28	$-0.59	$-0.51	$-0.32	$-0.82	$-0.74	$-0.73	$-0.18	$-1.59	$-1.73
Low Forecast	$-0.08	$-0.10	$-0.16	$-0.16	$-0.23	$-0.24	$-0.27	$-0.25	$-0.26	$-0.23	$-0.28	$-0.35	$-0.48	$-0.46	$-0.38	$-0.32	$-0.28	$-0.59	$-0.51	$-0.32	$-0.82	$-0.74	$-0.73	$-0.18	$-1.59	$-1.73
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.77%	0.50%	-	-	1.36%	1.09%	-	-	1.61%	0.57%	-	-	-1.39%	0.97%	-

According to 1 Wall Street analysts, aTyr Pharma's projected average Quarter EPS for Jul 20 is $-0.73, with a low estimate of $-0.73 and a high estimate of $-0.73. This represents a -392.00% decrease compared to LIFE previous annual EPS of $0.25 (Mar 20).

aTyr Pharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy

LIFE Forecast FAQ

Is aTyr Pharma a good buy?

Yes, according to 1 Wall Street analysts, aTyr Pharma (LIFE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of LIFE's total ratings.

What is LIFE's price target?

aTyr Pharma (LIFE) average price target is $11 with a range of $11 to $11, implying a 623.68% from its last price of $1.52. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will aTyr Pharma stock go up soon?

According to Wall Street analysts' prediction for LIFE stock, the company can go up by 623.68% (from the last price of $1.52 to the average price target of $11), up by 623.68% based on the highest stock price target, and up by 623.68% based on the lowest stock price target.

Can aTyr Pharma stock reach $2?

LIFE's average twelve months analyst stock price target of $11 supports the claim that aTyr Pharma can reach $2 in the near future.

What are aTyr Pharma's analysts' financial forecasts?

aTyr Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $104.17K (high $104.33K, low $104K), average EBITDA is $-62.5K (high $-62.4K, low $-62.599K), average net income is $-62.909M (high $-60.764M, low $-65.053M), average SG&A $1.13M (high $1.13M, low $1.13M), and average EPS is $-0.952 (high $-0.92, low $-0.984). LIFE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $644.7K (high $644.7K, low $644.7K), average EBITDA is $-387K (high $-387K, low $-387K), average net income is $-33.04M (high $-33.04M, low $-33.04M), average SG&A $7.01M (high $7.01M, low $7.01M), and average EPS is $-0.5 (high $-0.5, low $-0.5).

Did the LIFE's actual financial results beat the analysts' financial forecasts?

Based on aTyr Pharma's last annual report (Dec 2023), the company's revenue was $353K, which missed the average analysts forecast of $7.9M by -95.53%. Apple's EBITDA was $-54.919M, beating the average prediction of $-4.737M by 1059.26%. The company's net income was $-50.389M, missing the average estimation of $-72.198M by -30.21%. Apple's SG&A was $12.98M, missing the average forecast of $85.87M by -84.89%. Lastly, the company's EPS was $-94, beating the average prediction of $-1.093 by 8503.57%. In terms of the last quarterly report (Dec 2022), aTyr Pharma's revenue was $10.39M, beating the average analysts' forecast of $357.14K by 2808.08%. The company's EBITDA was $-7.95M, beating the average prediction of $-214K by 3610.01%. aTyr Pharma's net income was $-7.094M, missing the average estimation of $-31.719M by -77.63%. The company's SG&A was $3.43M, missing the average forecast of $3.88M by -11.80%. Lastly, the company's EPS was $-0.24, missing the average prediction of $-0.48 by -50.00%